

Background: Left ventricular thrombus (LVT) characteristically occurs in areas of dyskinesia or poorly contracting left ventricular muscle, caused by blood stasis and/or endocardial injury with associated inflammation. LVT can be a complication of myocardial infarction (MI) and occurs most often with large anterior MI¹. The risk of embolization within three months among patients with MI complicated by mural thrombus is 10-20% in the absence of systemic anticoagulation. It appears the risk of embolization is highest during the first 1-2 weeks, with subsequent risk decline over three months as the residual thrombus becomes endothelialized². Guideline recommendations regard warfarin as the treatment of choice for LVT, but this practice is mostly based on studies conducted on patients with MI before the era of PCI/stents. The role of DOACs, in the management of LVT has not been clear. No randomized controlled trials (RCTs) regarding treatment of LVT have been conducted for either warfarin or DOACs to date. Below is a summary of current guideline recommendations regarding the treatment of LVT and a brief review of published literature reporting the use of DOACs in the treatment of patients with LVT.

Bottom Line: Although warfarin is the treatment of choice according to guidelines, there has been an increasing trend of off-label use of DOACs for LVT treatment. Multiple case studies and retrospective cohort studies published involving the use of DOACs in the treatment of LVT have yielded promising results as it relates to thrombus resolution. However, in the recent RED VELVT¹⁰ study DOACs were associated with a higher risk of stroke or systemic embolism (SSE) than warfarin. These findings should be interpreted with caution given the study design (e.g. retrospective, observational), treatment crossovers, and unknown DOAC dosing regimens. Further, data from RED VELVT indicate that thrombus resolution may not correlate with reduced SSE risk. Given a lack of RCT data and considerable variability in presentation and associated complications of LVT, individualized approaches remain paramount. Further research on the efficacy and safety of warfarin and DOACs for the treatment of LVT is necessary. Patient-specific factors such as a history of labile INRs, time within therapeutic range, drug-drug interactions, end-organ function, bleeding risk, etc. should be considered when evaluating therapeutic options for LVT.

Guideline Recommendations

LVT Setting	Recommendation	Class of Recommendation/ Level of Evidence
2012 CHEST Guidelines¹		
LVT or high risk for LVT ^b + anterior MI with <u>NO STENT</u>	Warfarin (INR 2-3) + low dose aspirin x3 months^c. Then discontinue warfarin and continue DAPT for up to 12 months per ACS recommendations.	Grade 1B
LVT or high risk for LVT ^b + anterior MI with <u>BMS</u>	Warfarin (INR 2-3) + low dose aspirin + clopidogrel x1 month^a. Then warfarin + SAPT for 2 nd and 3 rd month. Then discontinue warfarin and continue DAPT for up to 12 months per ACS recommendations.	Grade 2C
LVT or high risk for LVT ^b + anterior MI with <u>DES</u>	Warfarin (INR 2-3) + low dose aspirin + clopidogrel x3-6 months^a. Then discontinue warfarin and continue DAPT for up to 12 months per ACS recommendations.	Grade 2C
LVT + systolic LV dysfunction withOUT established CAD	Warfarin (INR 2-3) for at least 3 months^c.	Grade 2C
High risk for LVT ^b withOUT established CAD	No antiplatelet therapy or warfarin.	Grade 2C
2013 ACC/AHA STEMI Guidelines³		
Asymptomatic LV mural thrombus or at high risk for LVT ^b + STEMI	Warfarin (INR 2-3, or 2-2.5 in triple therapy) x3 months^c.	Class IIa
2014 AHA/American Stroke Association Guidelines²		
Ischemic stroke or TIA in setting of acute MI complicated by LV mural thrombus	Warfarin (INR 2-3) x3 months^c.	Class I
Ischemic stroke or TIA in setting of acute MI complicated by LV mural thrombus <u>INTOLERANT</u> to VKA therapy	LMWH, dabigatran, rivaroxaban, or apixaban x3 months^c.	Class IIb
Ischemic stroke or TIA in setting of acute MI with high risk for LVT ^b	May consider warfarin (INR 2-3) x3 months^c.	Class IIb
Ischemic stroke or TIA in sinus rhythm who have left atrial or LVT.	Warfarin (INR 2-3) x3 months^c.	Class I
Ischemic stroke or TIA in sinus rhythm at high risk for LVT ^b	Effectiveness of anticoagulation is uncertain, treatment choice should be individualized.	Class IIb
2017 European Society of Cardiology STEMI Guidelines⁴		
LVT	Anticoagulation^d for up to 6 months guided by repeated imaging.	Class IIa

Treatment of LVT with DOACs in the Literature^e

Publication Date/Type	# Pts	Anticoagulant	Treatment Outcomes
Feb 2018; Systematic Review ⁵	15	Rivaroxaban	73% resolved. Duration ranged 7-436 days.
Jan 2019; Systematic Review ⁶	41	Apixaban; 11 pts Rivaroxaban; 21 pts Dabigatran; 9 pts	Apixaban: 100% resolved; median 36 days. Rivaroxaban: 81% resolved; median 40 days. Dabigatran: 89% resolved; median 24 days.
April 2019; Systematic Review ⁷	52	Apixaban; 10 pts Rivaroxaban; 30 pts Dabigatran; 12 pts	Apixaban: 100% resolved; median 36 days. Rivaroxaban: 90% resolved; median 90 days. Dabigatran: 75% resolved; median 28 days.
April 2019; Retrospective cohort study ⁸	108	Apixaban; 3 pts Rivaroxaban; 1 pt Warfarin; 94 pts LMWH; 10 pts	Apixaban: 100% resolved at 1yr. Rivaroxaban: 100% resolved at 1yr. Warfarin: 75% resolved at 1yr. LMWH: 40% resolved at 1yr. Duration varied.
May 2019; Retrospective cohort study ⁹	35	Apixaban; 16 pts Rivaroxaban; 17 pts Dabigatran; 2 pts	Apixaban: 76% resolved. Rivaroxaban: 76% resolved. Dabigatran: 50% resolved. Duration and f/u varied.
April 2020; Retrospective cohort Study ¹⁰ (RED VELVT)	514	DOAC; 121 pts Warfarin; 236 pts (64 pts switched between treatment groups, 93 pts not treated)	DOAC: 17 SSE events, 14 deaths, 8 bleeds. Warfarin: 14 SSE events, 32 deaths, 19 bleeds. Duration and f/u varied.

Key ACS- Acute coronary syndrome; **BMS**-Bare metal stent; **CAD**-Coronary artery disease; **DAPT**-Dual antiplatelet therapy; **DES**-Drug eluting stent; **DOAC**-Direct oral anticoagulant; **INR**-International normalized ratio; **LMWH**-Low molecular weight heparin; **MI**- Myocardial infarction
RCT-Randomized controlled trials; **SAPT**- Single antiplatelet therapy; **STEMI**- ST elevated MI **TIA**-Transient Ischemic attack **VKA**-Vitamin K antagonist

^aMust weigh potential risks vs. benefits of adding warfarin to DAPT. Duration of triple therapy, if chosen, should be minimized. For pts with large anterior STEMI and demonstrated LV thrombus, addition of warfarin to DAPT would be expected to result in 44 fewer nonfatal strokes and 15 more nonfatal extracranial bleeds per 1,000 patients treated. For pts with large anterior STEMI and no LV thrombus, adding warfarin to DAPT would prevent 7 nonfatal strokes at a cost of 15 nonfatal extracranial bleeds per 1,000 patients treated.

^bEF <40%, antero-apical wall motion abnormality.

^cPatients with persistent mobile or protruding thrombus visualized by echo or another imaging modality may remain at increased risk for stroke and other embolic events beyond 3 months.

^dNo recommendation for type of OAC. Bleeding risk and need for concomitant antiplatelet therapy should be considered.

^eReferenced literature employed various dosing strategies. (e.g. standard vs. initial VTE treatment DOAC dosing or warfarin with or without heparin overlap). Specific dosing recommendations are outside the scope of this review and have been omitted from this document. However, factors that should be considered when selecting a strategy include whether thrombus is mobile/protruding, appears "new" in nature, and patient bleeding risks.

References:

- Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schunemann HJ. American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel. Executive summary: antithrombotic therapy and prevention of thrombosis, 9th ed.: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest* 2012; 141:75-475.
- Kernan WN, Ovbiagele B, Black HR, et al; American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, and Council on Peripheral Vascular Disease. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for health-care professionals from the American Heart Association/American Stroke Association. *Stroke* 2014;45(7):2160-2236.
- O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. *Circulation* 2013;127(4):362-425.
- Ibanez B, James S, Agewall S, et al; ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). *Eur Heart J* 2018;39(2):119-177.
- Yassin, Ahmed & Abubakar, Hossam & Mishra, Tushar & Adam, Omeralfarouq & Hartman, Melanie & Pahuja, Mohit & Shokr, Mohamed. Rivaroxaban for Left Ventricular Thrombus. *Am J Ther*. 2018;26. 1. doi: 10.1097/MJT.0000000000000726.
- Kajm M, Shokr M, Ramappa P. Use of direct oral anticoagulants in the treatment of left ventricular thrombus: Systematic review of current literature. *Am J Ther*. 2019; doi: 10.1097/MJT.0000000000000937.
- Turgay, Yildirim O, Akti E, Aydin F, et al. Efficacy of direct oral anticoagulants on left ventricular thrombus. *Blood Coagul Fibrinolysis*. 2019;30:96-103. doi: 10.1097/MBC.0000000000000801.
- McCarthy CP, Murphy S, Venkateswaran RV, Singh A, Chang LL, Joice MG, et al. Left ventricular thrombus: Contemporary etiologies, treatment strategies, and outcomes. *J Am Coll Cardiol*. 2019;73:2007-9.
- Fleddermann AM, Hayes CH, Magalski A, Main ML. Efficacy of direct acting oral anticoagulants in treatment of left ventricular thrombus. *Am J Cardiol*. 2019; doi: 10.1016/j.amjcard.2019.05.009.
- Robinson AA, Trankle CR, Eubanks G, et al. Off-label use of direct oral anticoagulants compared with warfarin for left ventricular thrombi. *JAMA Cardiol*. Published online April 22, 2020. doi:10.1001/jamacardio.2020.0652.